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Scope: The aim of these guidelines is to provide recommendations for decolonizing regimens targeting
multidrug-resistant Gram-negative bacteria (MDR-GNB) carriers in all settings.
Methods: These evidence-based guidelines were produced after a systematic review of published studies
on decolonization interventions targeting the following MDR-GNB: third-generation cephalosporin-
resistant Enterobacteriaceae (3GCephRE), carbapenem-resistant Enterobacteriaceae (CRE),
aminoglycoside-resistant Enterobacteriaceae (AGRE), ﬂuoroquinolone-resistant Enterobacteriaceae
(FQRE), extremely drug-resistant Pseudomonas aeruginosa (XDRPA), carbapenem-resistant Acinetobacter
baumannii (CRAB), cotrimoxazole-resistant Stenotrophomonas maltophilia (CRSM), colistin-resistant
Gram-negative organisms (CoRGNB), and pan-drug-resistant Gram-negative organisms (PDRGNB). The
recommendations are grouped by MDR-GNB species. Faecal microbiota transplantation has been dis-
cussed separately. Four types of outcomes were evaluated for each target MDR-GNB:(a) microbiological
outcomes (carriage and eradication rates) at treatment end and at speciﬁc post-treatment time-points;
(b) clinical outcomes (attributable and all-cause mortality and infection incidence) at the same time-
points and length of hospital stay; (c) epidemiological outcomes (acquisition incidence, transmission
and outbreaks); and (d) adverse events of decolonization (including resistance development). The level
of evidence for and strength of each recommendation were deﬁned according to the GRADE approach.
Consensus of a multidisciplinary expert panel was reached through a nominal-group technique for the
ﬁnal list of recommendations.eases Section, Department of
i”, P.le L.A. Scuro 10, 37134,
onelli).
Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under
g/licenses/by-nc-nd/4.0/).
E. Tacconelli et al. / Clinical Microbiology and Infection 25 (2019) 807e817808Recommendations: The panel does not recommend routine decolonization of 3GCephRE and CRE car-
riers. Evidence is currently insufﬁcient to provide recommendations for or against any intervention in
patients colonized with AGRE, CoRGNB, CRAB, CRSM, FQRE, PDRGNB and XDRPA. On the basis of the
limited evidence of increased risk of CRE infections in immunocompromised carriers, the panel suggests
designing high-quality prospective clinical studies to assess the risk of CRE infections in immunocom-
promised patients. These trials should include monitoring of development of resistance to decolonizing
agents during treatment using stool cultures and antimicrobial susceptibility results according to the
EUCAST clinical breakpoints. E. Tacconelli, Clin Microbiol Infect 2019;25:807
© 2019 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Multidrug-resistant Gram-negative bacteria (MDR-GNB),
including third-generation cephalosporin-resistant Enterobacteri-
aceae (3GCephRE), carbapenem-resistant Enterobacteriaceae (CRE),
Acinetobacter baumannii and Pseudomonas aeruginosa, are a critical
priority for new antibiotic research and development according to
the World Health Organization (WHO) [1]. One of the criteria
weighed by WHO experts for prioritization of antibiotic-resistant
bacteria was the availability of infection-control measures to
reduce the spread of infection in community and healthcare set-
tings. The most important criteria for prioritizing MDR-GNB were
not only an empty pipeline and high attributable mortality in se-
vere infections but also the dearth of effective infection control
measures against these pathogens [2e5].
Decolonization has been an effective tool for reduction of
morbidity and mortality from infections due to methicillin-
resistant Staphylococcus aureus (MRSA) [6]. The assumption un-
derlying decolonization in individuals colonized by MRSA is that
colonization increases the subsequent infection risk. A systematic
review of the link between colonization and subsequent MRSA
infection that included ten observational studies and 1170 patients
showed a four-fold increase in infection risk associated with colo-
nization [6]. Previous studies showed that colonization with MDR-
GNB increases the risk of infections [7e16]. A prospective obser-
vational study in 497 haematological patients identiﬁed previous
colonization with extended-spectrum b-lactamase-producing
Enterobacteriaceae (ESBL-E) as the most important risk factor for
ESBL-E bloodstream infections [7]. Previous colonization with
MDR-GNB also increases infection risk in transplant and intensive
care unit (ICU) patients and those undergoing major abdominal
surgery [8e16]. Several factors have been associated with carriage
phenotype: species and susceptibility pattern [17], host features,
antibiotic exposure duration and type, and the extent of contact
with healthcare environments [18e22].
The most extensive experience in MDR-GNB decolonization is
with selective digestive decontamination (SDD) in ICU patients, but
studies have shown conﬂicting results [12,13,23e26]. In randomized
controlled trials (RCTs) performed in ICUs with low MDR-GNB
endemicity, SDD signiﬁcantly reduced infections and mortality with
limited impact on new resistance selection [26e31]. Recently a study
performed in a high-endemicity ICU in Spain over 4 years showed
that SDD reduced MDR-GNB infections with a non-signiﬁcant in-
crease in resistance to decolonizing agents [32]. Major limitations of
these studies are heterogeneity in patient case mix, ward coloniza-
tion pressure, and agents combined in the decolonization protocols.
The most recently developed guidelines on prevention of CRE
spread in hospitalized patients, evaluating studies up to 2014, do
not advise for or against decolonization because of a very low level
of evidence [2e4]. The objective of these guidelines is to provide
evidence-based recommendations for decolonization of MDR-GNBcarriers, irrespective of age, co-morbidities and setting. Speciﬁcally,
we address the following questions:
(a) What decolonization regimens have been evaluated for pa-
tients colonized with the target MDR-GNB?
(b) Do we recommend decolonization for patients colonized
with the target MDR-GNB?
(c) What is the regimen of choice for patients colonized with the
target MDR-GNB?
Expected users in hospital and community healthcare settings
include infection control specialists, healthcare providers (clinical
medical, nursing and paramedical staff) and policy-makers.
Methods
These guidelines were developed by a multidisciplinary group of
experts, selected by the European Committee of Infection Control
(EUCIC) according to the European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) recommendations for developing
guidance documents. This expert panel reviewed the articles and
discussed evidence-based tables, evidence certainty classiﬁcation,
and recommendation strength in two meetings at ECCMID 2017 and
2018, and by teleconference. Consensus of panel members for the
ﬁnal list of recommendations was reached through a nominal-group
technique.
Literature search and data extraction
We began the guidelines development process with a system-
atic review of the published literature. The review protocol was
registered on the International Prospective Register of Systematic
Reviews (PROSPERO) (https://doi.org/10.15124/CRD42017082729)
and is available in full on the PROSPERO website (https://www.crd.
york.ac.uk/prospero/display_record.php?RecordID¼82729). The
protocol followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [33]. We included
all studies evaluating any decolonization regimen targeting pa-
tients colonized with MDR-GNB. Articles were identiﬁed through
computerized literature searches using PubMed, the Cochrane
Database of Systematic Reviews, the Cochrane Central Register of
Controlled Trials and Web of Science. The search was restricted to
full-text articles published in English without restriction of publi-
cation year. A combination of Medical Subject Headings and
equivalent terms was used in the search strategy (see Supple-
mentary material, Appendix S1). Literature searches for each target
organism were performed between 9 and 16 August 2017.
Two independent reviewers performed a two-stage selection
process. First, abstracts were screened against eligibility criteria and
duplicate and irrelevant documents were excluded. We excluded
studies involving universal decolonization (decolonization of all
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laxis, environmental decolonization, and in vitro and animal studies.
Next, full-text articles were assessed, study data (design, population,
target bacteria, intervention, comparison, treatment duration and
outcomes) were extracted from eligible articles, and references were
screened on title and abstract for further inclusion. At both stages
each article was reviewed by two reviewers, and any discrepancies
were resolved through discussion with a third reviewer (see ﬂow
charts in Supplementary material, Appendix S2).
A population/participant, intervention, comparator/control,
outcome, known as PICO, frameworkwas developed. Population: any
patient of any age in any community or healthcare setting with any
screening sample yielding one of the following MDR-GNB were
included: 3GCephRE, CRE, aminoglycoside-resistant Enterobacteri-
aceae (AGRE), ﬂuoroquinolone-resistant Enterobacteriaceae (FQRE),
extremely drug-resistant Pseudomonas aeruginosa (susceptibility
maintained to up to two antibiotic classes: aminoglycosides, anti-
pseudomonal carbapenem, antipseudomonal cephalosporin, anti-
pseudomonal ﬂuoroquinolone, antipseudomonal penicillin þ b-
lactamase inhibitor, monobactam, phosphonic acid, polymyxin [34]),
carbapenem-resistant Acinetobacter baumannii (CRAB), co-
trimoxazole-resistant Stenotrophomonas maltophilia, colistin-
resistant Gram-negative organisms, pan-drug-resistant (non-sus-
ceptible to all tested agents) Gram-negative organisms [34]. Inter-
vention: decolonization therapy, deﬁned as anymeasure that leads to
loss of detectable MDR-GNB carriage at any site. Decolonizing regi-
mens included topical agents, systemic therapy, antibiotic inhaled
therapy, natural compounds, bacteriophage therapy, alternative
treatments, and novel regimens undergoing trials. Controls: patients
receiving no intervention (spontaneous decolonization) or a second
decolonization measure were included. Outcomes: four outcome
typesdmicrobiological, clinical, epidemiological and adverse even-
tsdwere evaluated for each target organism. The microbiological
outcomesof carriage rateoreradication ratewereassessedatdifferent
time-points (at treatment end and at 7 days, 1 month, 6 months and
1 year after treatment). Clinical outcomes included attributable and
all-cause mortality and infection incidence at the same time-points,
and length of hospital stay. Epidemiological outcomes included
acquisition incidence, transmission, and outbreaks in hospitals,
healthcare settings or the community. Assessment of decolonization
adverse events included the investigation of resistance development.
Because of the expected paucity of RCTs and non-randomized
controlled trials, uncontrolled studies were also reviewed.
Quality assessment
The quality assessment was performed using the Effective
Practice and Organization of Care guidelines for RCTs [35] and the
NewcastleeOttawa Scale for non-randomized controlled trials [36].
Each article was assessed by two reviewers, and discrepancies were
resolved by a third reviewer. Evidence certainty of controlled
studies was classiﬁed as high, moderate, low or very low, and
recommendation strength was classiﬁed as strong or conditional
according to the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) system [37]. The panel also
assessed recommendations for research and possible conditional
use in restricted trials and good practice points. The Supplementary
material (Appendix S3) gives a detailed description of the GRADE
approach, grades of evidence and determinants of quality.
Results and recommendations
The guidelines are organized by target organism. Each section
reports the main characteristics of controlled studies, a summary of
the evidence, and a recommendation graded according to theavailable evidence. Flowcharts of assessed studies are included in the
Supplementary material (Appendix S2). No articles were found for
extremely drug-resistant Pseudomonas aeruginosa, co-trimoxazole-
resistant Stenotrophomonas maltophilia, colistin-resistant Gram-
negative organisms or pan-drug-resistant Gram-negative organisms.
Twelve studies were included for 3GCephRE,18 for CRE, six for CRAB,
one for FQRE and one for AGRE. Of these studies, two 3GCephRE
studies and seven CRE studies focused on faecal microbiota trans-
plantation (FMT) are discussed separately at the end of this section.
Tables 1e3 provide details of study designs and results.
Third-generation cephalosporin-resistant Enterobacteriaceae
Study characteristics
The ten studies were performed in Europe (nine studies) and the
USA (one study): two RCTs [38,39], two prospective cohort studies
[40,41], one uncontrolled nested post hoc analysis of a cluster-
randomized study with additional hospital data [42], and ﬁve
case series without comparators [43e47]. Only one study had a
multicentre design [42]. Two studies evaluated hospital patients
[38,39]; ﬁve evaluated ICU patients [41e43,45,47]; one evaluated
liver transplanted patients [46]; two studied outpatients [39,44],
and two studies were conducted in paediatric wards [43,45]. Four
studies were performed during a 3GCephRE outbreak [41,43,46,47],
three studies were performed in healthcare centres reporting
endemic 3GCephRE [40,44,45], and three studies did not specify
local epidemiology [38e40]. All studies performed rectal screening
[38e47], four included urine cultures [38,39,41,45], and two
included respiratory tract cultures [43,45].
Huttner et al. conducted an RCT to assess the efﬁcacy of oral non-
absorbable antibiotics on rectal ESBL-E carriage in hospital patients
[38]. Fifty-eight patients were allocated to either placebo or oral
colistin sulphate (50 mg (salt) four times daily) and neomycin sul-
phate (250mg (salt) four times daily) for 10 days (plus nitrofurantoin
for 5 days in the event of urine detection) [38]. Jonsson et al. assessed
the role of anti-ESBL immunoglobulin Y chicken antibodies in ESBL-E
faecal carriage eradication, randomizing 24 outpatients to either
active treatment or placebo [39]. The RCT was discontinued before
completion because of highdrop-out. In an8-year prospective cohort
study, Buehlmann et al. enrolled 35 asymptomatic ESBL-E carriers
and treated with chlorhexidine mouth rinse for 4 days for throat
colonization, oral paromomycin for 4 days for rectal colonization, or
oral nitrofurantoin or fosfomycin (single dose) or ciproﬂoxacin or
cotrimoxazole for 5 days for urinarycolonization [40]. The coursewas
repeated in patients with persistent ESBL-E carriage. Decre et al.
performed a prospective cohort trial of 404 patients colonized or
infected with ESBL-producing Klebsiella pneumoniae and compared
universal with target SDD using oral erythromycin (1 g twice daily)
and colistin sulphate (6million units twice daily) [41]. Decolonization
regimens in the six uncontrolled studies differed widely: the most
common agent was oral colistin alone [44] or combined with either
oral aminoglycosides (neomycin, amikacin, or tobramycin)
[42,43,45,47], erythromycin [47], rifaximin [44], or norﬂoxacin [46].
Treatment duration, when reported, ranged from 5 to 28 days.
Oostdijk et al. conducted a nested post hoc analysis without
comparator of a cluster-randomized multicentre trial in 13 Dutch
ICUs. Fifty patients received oropharyngeal application of a paste
containing colistin, tobramycin and amphotericin B, each at a con-
centration of 2%, and a 10-mL suspension containing 100 mg of
colistin, 80 mg of tobramycin, and 500 mg of amphotericin B via a
nasogastric tube. Topical antibiotics were applied four times daily
until discharge from ICU. In addition, intravenous cefotaxime (1000
mg, every 6 h)was administered for theﬁrst 4 days. Rectal carriage of
3GCephRE and AGREwas determined at admission and twiceweekly
during the ICU stay [42].
Table 1
Characteristics of 27 included studies (sorted by study design)
Author, year of
publication [ref.]
Study design Population Target bacteria Intervention Comparison Treatment duration
Saidel-Odes, 2012
[51]





RCT Mixed population CRE High-dose probiotics þ psyllium Standard care 14 days
Huttner, 2013 [38] RCT Mixed population 3GCephRE ESBL
producer
Colistin sulphate (1.26 MIU)
qid þ neomycin sulphate (80 mg) qid
Placebo 10 days
Jonsson, 2015 [39] RCT Mixed population 3GCephRE ESBL
producer
Anti-ESBL IgG Placebo 21 days
Tannock, 2011 [64] RCT Long-term care
facility residents
FQRE Probiotic strain E. coli Nissle 1917
(5 109 to 5 1010 bacteria daily, twice
daily)
Placebo 5 weeks
Oren, 2013 [53] Semi-randomized
trial
Mixed population CRE Gentamicin (80 mg) qid or colistin







Prospective cohort Mixed population 3GCephRE ESBL
producer
Paromomycin (1 g) qid (intestinal
colonization); chlorhexidine
(oropharyngeal application, 0.2%) tid
(throat colonization); nitrofurantoin
(100 mg) tid or ciproﬂoxacin (750 mg)
bid or cotrimoxazole (800/160 mg) bid








Decre, 1998 [41] Prospective cohort ICU 3GCephRE ESBL
producer





Borer, 2007 [65] Prospective cohort ICU CRAB Topical 4% chlorhexidine, one full body
wash daily
Standard care Not reported




Gentamicin (80 mg) qid or
streptomycin (80 mg) tid þ neomycin
(40 mg) tid
Standard care 14 days
Lubbert, 2013 [54] Retrospective
cohort
ICU CRE Colistin sulphate (1 MIU)




Agusti, 2002 [66] Caseecontrol ICU CRAB Colistin (150 mg) qid þ tobramycin
(80 mg) qid
Standard care Variable (mean,
35.8 days)
Chen, 2014 [67] Caseecontrol Mixed population CRAB Inhaled colistin (2 MIU/160 mg) bid Standard care Not reported
Kuo, 2012 [68] Caseecontrol Mixed population CRAB Inhaled colistin (2 MIU/160 mg) bid Standard care Variable
(10.9 ± 3.6 days)




Colistin (2 MIU) qid þ tobramycin
(80 mg) qid þ cefotaxime (1 g) qid
NA Up to ICU discharge
Gutierrez-Urbon,
2015 [43]
Case series Paediatric ICU 3GCephRE ESBL
producer
Colistin (solution 1%, 1 mL/kg)
qid þ amikacin (solution 3.2%, 1 mL/kg)
qid
NA 5 days
Rieg, 2015 [44] Case series Mixed population 3GCephRE ESBL
producer
Colistin standard dose (1 MIU) or high
dose (2 MIU) qid or rifaximin
NA 4 weeks
Abecasis, 2011 [45] Case series Paediatric ICU 3GCephRE ESBL
producer
Colistin þ tobramycin þ cefotaxime
(doses not speciﬁed)
NA Not reported
Paterson, 2001 [46] Case series SOT 3GCephRE ESBL
producer
Norﬂoxacin (400 mg) bid NA 5 days
Troche, 2005 [47] Case series ICU 3GCephRE ESBL
producer
2 among colistin sulphate (1.5 MIU) qid,
neomycin (500 mg) qid or
erythromycin (500 mg) qid
NA Not reported
De Rosa, 2016 [56] Case series Haematological
malignancy
CRE Gentamicin (80 mg) qid NA Variable (mean, 5 days)






CRE Gentamicin (80 mg) qid NA Up to eradication






CRE Gentamicin (80 mg) qid NA Up to eradication
(range, 7e25 days)
Gray, 2016 [69] Case series Mixed population CRAB Chlorhexidine gluconate-impregnated
wipes 2% daily
NA Not reported






CRE Gentamicin þ colistin (doses not
speciﬁed)
NA 10 days
Brink, 2013 [60] Case report Mixed population CRE Colistin þ tobramycin (doses not
speciﬁed)
NA Not reported
Abbreviations: AGRE. aminoglycoside-resistant Enterobacteriaceae; bid, twice daily; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant
Enterobacteriaceae; ESBL, extended-spectrum b-lactamase; FQRE, ﬂuoroquinolone-resistant Enterobacteriaceae; ICU, intensive care unit; IgG, immunoglobulin G; NA, not
applicable; qid, four times daily; RCT, randomized controlled trial; SOT, solid organ transplant; 3GcephRE, third-generation cephalosporin-resistant Enterobacteriaceae; tid,
thrice daily.
E. Tacconelli et al. / Clinical Microbiology and Infection 25 (2019) 807e817810
E. Tacconelli et al. / Clinical Microbiology and Infection 25 (2019) 807e817 811Clinical outcomes
Two case series [43,45] and the nested post hoc analysis [42]
included clinical outcomes (all-cause mortality at treatment end
or length of stay)dAbecasis et al. reported a 20.5% (8/39) mortality
rate [45] and Gutierrez-Urbon et al. reported no deaths [43].
Oostdijk et al. observed a median ICU stay of 12 days (range 3e77;
interquartile range (IQR), 10) for 3GCephRE-colonized patients and
13 days (range 3e77; IQR, 11) for decolonized patients [42].
Microbiological outcomes
One RCT [38], one prospective cohort study [40] and all studies
without comparator [42e47] included microbiological outcomes
(carriage rate or eradication rate). Huttner et al. observed a signif-
icantly lower rectal carriage rate in the treatment group than in the
placebo group at treatment end (32.0% (8/25) versus 76.9% (20/26);
p 0.001), but the effect was lost at 7 days post-treatment (66.7% (18/
27) versus 68% (17/25); p 0.92) and at 28 days post-treatment
(51.9% (14/27) versus 37% (10/27); p 0.28) [38]. Buehlmann et al.
showed that repeated decolonization signiﬁcantly improved erad-
ication rate at treatment end (88.9% (16/18) versus 41.1% (7/17); p
0.007) [40]. The studies without comparator reported decoloniza-
tion rates at treatment end ranging from no effect to 100% [42e47].
Epidemiological outcomes
One prospective cohort study [41] evaluated the impact of
decolonization regimen on epidemiological outcomes (incidence of
acquired colonization and acquired infections). No signiﬁcant dif-
ference from the historical control group was observed in the inci-
dence of acquired 3GCephRE colonization in the digestive tract (10%
versus 9.1%) or in the incidence of acquired infections (7.5% versus
3.6%).
Adverse events
Resistance development was assessed in one RCT and one un-
controlled study [38,42]. Huttner et al. observed no statistically sig-
niﬁcant changes in the colistin or neomycin MICs between baseline
and ﬁnal ESBL-E isolates in the treatment group [38]. Oostdijk et al.
found no association with increased resistance over time when
eradication failed [42]. Adverse events were evaluated in two RCTs
[38,39] and one study without comparator [43]. In the Huttner et al.
trial, 7/27 (25.9%) patients in the treatment group versus 2/29 (6.9%)
patients in the placebo group (p 0.05) experienced liquid stool during
follow up [38], whereas in the Jonsson study the proportion of par-
ticipants who reported various adverse events was similar between
the treatment and the placebo groups (58% versus 42%) [39].
Other relevant outcomes
A signiﬁcantly lower rectal carriage rate was observed by
Huttner et al. on day 6 of treatment (9/26 (34.6%) versus 19/22
(86.3%); p < 0.001) [38].
Evidence evaluation
Evidence was of moderate [38] and very low [40] certainty for
microbiological eradication at treatment end, low for microbio-
logical eradication at 7 days and 28 days post-treatment [38] and
for resistance development [38], and very low for adverse events
[38,39].
Recommendation
The panel does not recommend routine decolonization of
3GCephRE carriers.
Grading: conditional recommendation against the intervention.Research and possibly conditional use in restricted trials
On the basis of the limited evidence of temporary effectiveness
of decolonization [38,40] and the increased risk of developing
ESBL-E bloodstream infections in neutropenic colonized patients
[7,48,49], the panel suggests designing clinical trials of decoloni-
zationwith oral colistin sulphate (50mg (salt) four times daily) and
neomycin sulphate (250 mg (salt) four times daily) to temporarily
suppress 3GCephRE carriage in patients with severe neutropenia
(absolute neutrophil count <500 mL). These trials should include
careful monitoring for development of resistance to neomycin or
colistin during decolonization using stool cultures and antimicro-
bial susceptibility results according to the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints
[50].Carbapenem-resistant Enterobacteriaceae
Study characteristics
The 11 studies were performed in Europe (6), Israel (3), South
Africa (1) and the USA (1): two RCTs [51,52], one semi-randomized
control trial [53], two retrospective cohort studies [54,55], and six
case series and case reports without comparators [56e61]. Two
studies had a multicentre design [55,59]. Six studies evaluated
hospital inpatients [51e53,55,59,60], one assessed ICU patients
[54], and four evaluated haematological patients [56,57,59,61]. Four
studies were performed during a CRE outbreak [54,55,57,60]. Seven
studies did not specify local epidemiology [51,53,55,56,58,59,61].
Rectal carriage testing was performed in all studies, and urinary
carriage and respiratory tract colonization were assessed in one
study each [51,54].
Saidel-Odes et al. conducted an RCT to test the efﬁcacy of
intestinal decontamination on CRE carriage. Forty patients were
randomized to receive either placebo or colistin (1 MU four times
daily) and gentamicin sulphate (80 mg four times daily) for
7 days [51]. Nouvenne et al. performed an RCT in 32 patients
assessing the role of high-dose probiotics in CRE faecal carriage
eradication. The patients were randomly assigned to either high-
dose probiotics and psyllium for 14 days or standard care [52].
Oren et al. evaluated 50 patients treated with one of three regi-
mens: colistin sulphate (2 MU four times daily), gentamicin
sulphate (80 mg four times daily), or both [53]. The patients were
assigned to antibiotic regimens either according to susceptibility
or randomly (for carriers of strains susceptible to both colistin
and gentamicin). Patients undergoing treatment were compared
with controls (102 patients) for eradication and clinical out-
comes. Machuca et al. analysed a retrospective cohort of 77 pa-
tients using two regimens: gentamicin solution (80 mg four
times daily) or streptomycin sulphate (80 mg three times daily)
and neomycin (40 mg three times daily) for 14 days [55]. Lubbert
et al. analysed a retrospective cohort of 16 ICU patients treated
for 7 days with colistin sulphate (1 MU four times daily) and
gentamicin sulphate (80 mg four times daily) [54].Clinical outcomes
All controlled studies [51e55] and four studies without
comparator [56e60] included clinical outcomes (all-cause and
attributable mortality, CRE-related infection incidence or length of
hospital stay). Machuca et al. reported a signiﬁcant reduction in all-
cause mortality associated with the use of decolonization therapy
at 6 months after treatment end (25% versus 54%; hazard ratio (HR)
0.18; 95% CI 0.06e0.55) [55]. Oren et al. observed a reduction in all-
cause mortality without impact on attributable mortality during
the follow-up period (timing not speciﬁed) (22% (11/50) versus 53%





Target bacteria Sample size Time-point Eradication rate 95% CI p value
Saidel-Odes, 2012
[51]
CRE Intervention 20; control 20 7 days after EoT









CRE Intervention 18; control 14 NA 53% vs. 12% NA 0.0094
Huttner, 2013 [38] 3GCephRE ESBL
producer
Intervention 27; control 27 EoT







Tannock, 2011 [64] FQRE Intervention 36; control 33 5 weeks after EoT 23% vs. 42% NA NS
Oren, 2013 []53 CRE Intervention 50; control
102





Intervention 18; control 17 EoT OR, 11.42 1.6e102.6 NA
Machuca, 2016 [55] CRE Intervention 44; control 33 6 months after EoT aHR, 4.06 1.06e15.6 0.04
Lubbert, 2013 [54] CRE Intervention 16; control 76 NA 57% vs. 83% NA NS
Agusti, 2002 [66] CRAB Intervention 33; control 21 EoT 52% vs. 9% NA <0.001
Chen, 2014 [67] CRAB Intervention 81; control 54 14 days after EoT







Kuo, 2012 [68] AGRE Intervention 39; control 39 14 days after EoT












Intervention 6; control NA EoT 0% NA NA
Rieg, 2015 [44] 3GCephRE ESBL
producer
Intervention 45; control NA 14 days after EoT Colistin SD 39%; colistin
HD 25%; rifaximin 60%
NA NA
Abecasis, 2011 [45] 3GCephRE ESBL
producer
Intervention 39; control NA EoT 77% NA NA
Paterson, 2001 [46] 3GCephRE ESBL
producer
Intervention 9; control NA EoT
14 days after EoT





Troche, 2005 [47] 3GCephRE ESBL
producer
Intervention 37; control NA EoT 46% NA NA
De Rosa, 2016 [56] CRE Intervention 8; control NA NA 25% NA NA
Tascini, 2014 [59] CRE Intervention 50; control NA NA 68% NA NA
Zuckerman, 2011
[57]
CRE Intervention 15; control NA NA 66% NA NA
Lambelet, 2017
[58]
CRE Intervention 14; control NA NA 71% NA NA
Hseih, 2014 [70] CRAB Intervention:
- Colonized group 61







CRE Intervention 1; control NA 28 days after EoT 100% NA NA
Brink, 2013 [60] CRE Intervention 1; control NA EoT 0% NA NA
Abbreviation: aHR, adjust hazard ratio; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum b-
lactamase; EoT, end of treatment; FQRE, ﬂuoroquinolone-resistant Enterobacteriaceae; HD, high dose; NA, not applicable; NS, not signiﬁcant; OR, odds ratio; SD, standard
dose; 3GcephRE, third-generation cephalosporin-resistant Enterobacteriaceae.
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during hospitalization [52,54].
Machuca et al. reported a signiﬁcant reduction in the CRE-
related infection incidence at 6 months follow up (4.5% (2/44)
versus 39.4% (13/33); p < 0.001) [55]. Univariate analysis demon-
strated a lower risk of carbapenemase-producing K. pneumoniae
infections in the follow-up period associated with decolonization
(HR 0.14; 95% CI 0.02e0.83). Only gentamicin was signiﬁcantly
associated with infection rate reduction in the analysis stratiﬁed by
treatment (crude HR 0.86; 95% CI 0.008e0.94). Two studies ana-
lysing the effect of decolonization on length of hospital stay found
no difference between treated and untreated patients [51,54].
Microbiological outcomes
All controlled studies [51e55] and all studies without compar-
ator [56e61] included microbiological outcomes (carriage rate or
eradication rate). In the RCT by Saidel-Odes et al., signiﬁcant car-
riage rate reduction was observed 7 days post-treatment (38.8%versus 83.9%; OR 0.13; 95% CI 0.02e0.74; p < 0.0016), but the effect
was lost at 28 days, resulting in a non-signiﬁcant difference be-
tween the two groups (41.5% versus 66.7%) [51]. In the RCT by
Nouvenne et al., signiﬁcant reduction in carriage rate during hos-
pitalization was associated with administration of high-dose pro-
biotics (p 0.009) [52]. In the semi-randomized trial by Oren et al.,
the eradication rate during follow upwas signiﬁcantly higher in the
intervention group (56% (22/50) versus 7% (7/102); p < 0.001) [53].
The retrospective cohort study byMachuca et al. found a signiﬁcant
difference in decolonization rate between the control and treated
groups (51.1% versus 9.1%; p < 0.001) at 180 days post-treatment
(HR 4.06; 95% CI 1.06e15.6) [55]. When stratiﬁed by treatment
regimen, gentamicin was associated with a signiﬁcantly higher
microbiological success rate (HR 5.67; 95% CI 1.33e24.1). The other
regimen (streptomycin and neomycin combination) showed no
signiﬁcant association. The retrospective cohort study by Lubbert
et al. showed no signiﬁcant difference in the decolonization rate
between the two groups [54].
Table 3
Clinical outcomes
Author, year of publication [ref.] Target bacteria Sample size Clinical outcome Time-point Effect size 95% CI p value
Nouvenne, 2015 [52] CRE Intervention 18; control 14 All-cause mortality NA 31% vs. 12% NA NS
Oren, 2013 [53] CRE Intervention 50; control 102 All-cause mortality
Attributable mortality






Machuca, 2016 [55] Colistin-resistant CRE Intervention 44; control 33 All-cause mortality
Incidence of infection
6 months after EoT







Lubbert, 2013 [54] CRE Intervention 16; control 76 All-cause mortality
Incidence of infection
















Chen, 2014 [67] CRAB Intervention 81; control 54 All-cause mortality 28 days after EoT 15% vs. 7% NA NS
Kuo, 2012 [68] CRAB Intervention 39; control 39 All-cause mortality
Incidence of infection








Gutierrez-Urbon, 2015 [43] 3GCephRE
ESBL producer
Intervention 6; control NA All-cause mortality EoT 0% NA NA
Abecasis, 2011 [45] 3GCephRE
ESBL producer
Intervention 39; control NA All-cause mortality EoT 21% NA NA
De Rosa, 2016 [56] CRE Intervention 8; control NA Incidence of infection 6 months after EoT 37% NA NA
Tascini, 2014 [59] CRE Intervention 50; control NA Incidence of infection NA 36% NA NA



















Hseih, 2014 [70] CRAB Intervention:
- colonized group 61
- pneumonia group 57
Control NA
All-cause mortality 28 days after EoT 28%
33%
NA NA
Abbreviations: aHR, adjust hazard ratio; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum b-
lactamase; EoT, end of treatment; NA, not applicable; NS, not signiﬁcant; 3GcephRE, third-generation cephalosporin-resistant Enterobacteriaceae.
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None of the studies evaluated epidemiological outcome.
Adverse events
Resistance development was assessed in one RCT [51], three
controlled studies [53e55] and all studies without comparator
[56e61]. Among controlled studies, an increase in secondary
resistance to decolonizing agents was reported in three studies
[53e55]. Machuca et al. found that a signiﬁcantly higher proportion
of patients undergoing decolonization had gentamicin-resistant
isolates in follow-up cultures than those not treated (13% (6/44)
versus 3% (1/33); p 0.008) [55]. In the Oren et al. and Lubbert et al.
studies, 14% (7/50) and 28% (4/14) of patients, respectively, devel-
oped secondary resistance to decolonizing agents [53,54]. Saidel-
Odes et al. did not observe increased resistance in their RCT [51].
None of the controlled studies reported a higher adverse event
incidence in the intervention group.
Evidence evaluation
Evidence was of low certainty for microbiological eradication at
1 week [51] and 6 months [55] post-treatment and CRE infection
incidence at 6 months [55], and of very low certainty for microbi-
ological eradication at 4 weeks [51] and all-cause mortality [55].
Recommendation
The panel does not recommend routine decolonization of CRE.
Grading: conditional recommendation against the intervention.
Research and possibly conditional use in restricted trials
On the basis of the limited evidence of increased risk of devel-
oping CRE infections in the colonized ICU population [12,13,62,63]
and the results of the effectiveness of decolonization on CREcarriers [51,53], the panel suggests designing good-quality clinical
studies to assess CRE infection risk in colonized haematological
patients and solid organ transplant recipients. The panel further
suggests using the results of these trials to design decolonization
trials with oral colistin sulphate (50 mg (salt) four times daily) with
or without gentamicin sulphate (80 mg (salt) four times daily) to
temporarily suppress CRE carriage in high-risk patients. These trials
should include careful monitoring of development of resistance to
gentamicin and colistin during decolonization using stool cultures
and antimicrobial susceptibility results according to the EUCAST
clinical breakpoints [50].Fluoroquinolone-resistant Enterobacteriaceae
Study characteristics
Tannock et al. conducted a multicentre RCT in New Zealand to
evaluate the efﬁcacy of the probiotic strain Escherichia coli Nissle
1917 on FQRE colonization [64]. Sixty-nine elderly residents in
long-term care facilities excreting norﬂoxacin-resistant E. coliwere
randomized to receive either probiotic (5  109 to 5  1010 bacteria
daily, one capsule twice daily) or placebo for 5 weeks. Rectal and
urinary carriage testing were assessed in the trial.Clinical outcomes
No clinical outcome was assessed.Microbiological outcomes
No signiﬁcant difference was found in decolonization rate be-
tween the control and treated groups at 5 weeks post-treatment.Epidemiological outcomes
No epidemiological outcome was analysed.
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No adverse event was evaluated.
Evidence evaluation
Evidence was of low certainty for microbiological eradication at
5 weeks post-treatment.
Recommendation




The Oostdijk et al. study [42] is described above in the 3GCephRE
section.
Clinical outcomes
Median length of ICU stay was 11.5 days (range 4e82; IQR 9.5)
for AGRE-colonized patients and 12 days (range, 4e82; IQR 8) for
decolonized patients.
Microbiological outcomes
The eradication rate was 62% (31/50) after a median of 5.5 days
(IQR 3e60 days) of decolonization.
Epidemiological outcomes
No epidemiological outcome was analysed.
Adverse events
No increased resistance overtime was seen when eradication
failed.
Recommendation




Three studies were performed in Taiwan and one each in Can-
ada, Spain and Israel: one prospective cohort study [65], three
caseecontrol studies [66e68] and two case series without com-
parators [69,70]. All studies had a single-centre design. Four studies
evaluated hospital patients [67e70] and two studied ICU patients
[65,66]. Two studies were performed during a CRAB outbreak
[66,69], one study was performed in a centre where CRAB was
endemic [65], and three studies did not specify local epidemiology
[67,68,70]. Respiratory tract cultures were performed in three
studies [67,68,70], skin cultures in three studies [65,66,69], and
rectal screening in two studies [66,69].
Borer et al. prospectively evaluated the impact of daily 4%
chlorhexidine body wash in a cohort of 320 ICU patients [65]. Two
controlled [67,68] studies and one case series [70] compared
inhaled colistin (160 mg twice daily) with variable duration
(7.3e13.5 days) to standard care in hospital patients. One controlled
study [65] and one uncontrolled study [69] evaluated topical
chlorhexidine during hospitalization. In one caseecontrol study 21
ICU patients receiving an SDD regimen of colistin sulphate (50 mg
(salt) four times daily) and tobramycin (80 mg four times daily)
were compared to 33 ICU patients receiving standard care until
discharge [66]. Gray et al. described the management of a CRAB ICU
outbreak involving 29 patients using a multimodal intervention
including 2% chlorhexidine washes; in this case series none of the
outcomes evaluated in this systematic review were assessed [69].Clinical outcomes
Three caseecontrol studies [66e68], one prospective cohort
study [65], and one uncontrolled study [70] assessed clinical out-
comes (all-cause mortality and infection rate). No signiﬁcant dif-
ference in all-cause mortality during ICU stay was observed after
oral decolonization [66]. All-cause mortality was assessed in two
case-control studies comparing inhaled colistin with standard care,
and no signiﬁcant differences in mortality was observed [67,68].
Only Borer et al. observed a signiﬁcant reduction in CRAB blood-
stream infections after the intervention (0.6% versus 4.65%;
p < 0.001) [65].
Microbiological outcomes
Three studies evaluated eradication rate [66e68]. Persistent
CRAB carriage 14 days after treatment was assessed in two
controlled studies. Chen et al. observed 14-day eradication in 54.3%
of patients receiving decolonization versus 29.6% of controls (p
0.005), although a signiﬁcant association was not observed for 28-
day eradication rates (66.7% versus 51.9%; p 0.084) [67]. Kuo et al.
observed a signiﬁcant 14-day eradication rate (84.6% versus 10.3%;
p < 0.001) [68]. Agusti et al. found signiﬁcant reduction in faecal
(48% versus 91%; p 0.001) and pharyngeal (38% versus 78%; p 0.03)
carriage at discharge in patients who received SDD compared with
controls. SDD did not affect cutaneous carriage [66].
Epidemiological outcomes
No epidemiological outcome was analysed.
Adverse events
Kuo et al. assessed colistin resistance development, speciﬁcally
changes in colistin MIC (one-fold to two-fold) between isolates
cultured from the same patients. No signiﬁcant difference between
case and control groups was observed (8/28 (28.6%) versus 4/30
(13.3%); p 0.15) [68].
Evidence evaluation
Evidence was of very low certainty for all the assessed
outcomes.
Recommendation
Evidence is insufﬁcient to provide a recommendation for or
against any intervention.
Faecal microbiota transplantation
Faecal microbiota transplantation is the administration of
thoroughly screened, healthy-donor stool into a patient's gut,
either into the colon (via enema or colonoscope) or into the upper
small intestine (via nasojejunal tube or swallowed capsules) [71].
The potential beneﬁt of FMT as an MDR-GNB decolonization
strategy has been tested in nine uncontrolled studies with a high
level of heterogeneity [72e80].
A single-centre study by Bilinski et al. investigated the use of
FMT for MDR-GNB eradication in patients with haematological
disorders [72]. Twenty-ﬁve FMTs were performed in 20 patients
with intestinal MDR-GNB colonization, mainly carbapenemase- or
ESBL-producing Enterobacteriaceae. Complete decolonization was
achieved in 60% (15/25) of the cases at 1 month and in 13/14 (93%)
of cases at 6 months post-treatment. Antibiotic use within 7 days
post-treatment hampered the effectiveness of the intervention.
Davido et al. reported the results of a series of eight FMTs, of
which six were performed in patients colonized with
carbapenemase-producing Enterobacteriaceae [73]. Eradicationwas
obtained in two patients at 1 month post-treatment. No relapse of
Table 4
Characteristics and results of nine studies on faecal microbiota transplantation
Author, year [ref.] Population Target bacteria Study design Time-point after EoT Successful eradication




















Friedman-Moraco, 2014 [78] Haematological malignancy CRE Case report EoT 1/1




Lagier, 2013 [77] Mixed population CRE Case report 1 week 1/1
Ponte, 2017 [76] Mixed population CRE Case report 1 month 1/1
Abbreviations: CRE, carbapenem-resistant Enterobacteriaceae; EoT, end of treatment; 3GcephRE, third-generation cephalosporin-resistant Enterobacteriaceae.
Key points
 The panel does not recommend routine decolonization of
MDR-GNB carriers.
 The effectiveness and long-term side effects of decoloni-
zation of 3GCephRE and CRE in high-risk populations (e.g.
ICU, neutropenic and transplant populations) needs to be
evaluated with RCTs with proper design and sample size
calculation.
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provides details of study design and results.
Recommendation
Evidence is insufﬁcient to provide a recommendation for or
against FMT. Further studies are warranted to evaluate the effec-
tiveness, applicability, and safety of FMT to conﬁrm its role in in-
testinal decolonization of MDR-GNB.
Limitations of the evidence and future research
Our systematic review has identiﬁed important gaps in the
literature on targeted decolonization strategies in MDR-GNB car-
riers. Studies have been evaluated for only a few clinically relevant
MDR-GNB in speciﬁc settings, and, of those assessed, data are
insufﬁcient to provide robust recommendations on decolonization.
High heterogeneity was detected among studies and did not allow
anymeta-analytic approach but only a qualitative review. The panel
identiﬁed the following major ﬂaws in the evaluated evidence:
inconsistent reporting, small sample size, key outcomes not
assessed, inconsistent effectiveness deﬁnition, colistin susceptibil-
ity testing not in accordance with current recommendations, and
wide heterogeneity between settings (outbreak, endemic), decol-
onization regimens and treatment duration. The assessment typi-
cally evaluated a single intervention although multiple infection
control measures are often implemented together as a bundle in
clinical practice.
Because of the lack of effective drugs for MDR-GNB, the devel-
opment of novel decolonization strategies through well-designed
in vitro and in vivo studies is urgently needed [81]. These strate-
gies may include natural compounds (FMT, prebiotics, probiotics),
alternative therapies (tea tree oil, photodynamic therapies, omi-
ganan pentahydrochloride), and bacteriophage therapy. Well-
designed multicentre RCTs are required to determine the impact
of decolonization strategies on microbiological, epidemiological
and clinical outcomes and development of resistance. Furthermore,
the studies should evaluate the optimal dosing, duration, target
populations and setting (endemic versus outbreak), and cost-
effectiveness. Sequential interventions (e.g. oral SDD followed by
FMT) should be explored. Evaluation of the efﬁcacy of multimodal
decolonization methods in stepped-wedge cluster RCTs should also
be considered. Metagenomic studies assessing the effect of
decolonizing agents on the microbiota composition and dynamics
could provide valuable evidence for designing RCTs and drivechoices of old and new drugs to be tested. Although it is under-
standable that research to date has focused on organisms with
current signiﬁcant clinical impact (3GCephRE, CRE, CRAB), we
should not neglect other MDR-GNB (e.g. extremely drug-resistant
Pseudomonas aeruginosa, pan-drug-resistant Gram-negative or-
ganisms) for which current experience is low but is likely to in-
crease in the future.Transparency declaration
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Evelina Tacconelli and the current expert group are responsible
for updating these guidelines with a time frame of 2 years between
publishing and commencing the next updating process. If high-
quality evidence is published within the 2-year time frame, the
group will analyse the data and report to the scientiﬁc community
in a timely manner.
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